Observational studyHaematologica2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
Observational study in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- The transcriptomic profile of CD138Haematologica · 2019Trial
- Serum free light chain concentration and ratio-based criterion for myeloma-defining event, in its current version, is untenable.British journal of haematology · 2026Review
- Review
- Primum non nocere: a critical analysis of early intervention clinical trials in smoldering multiple myeloma.Frontiers in oncology · 2026Review
- Navigating the evolving management of smoldering multiple myeloma.HemaSphere · 2026Review
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma.Cancer biomarkers : section A of Disease markers · 2025Article
- Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma.Research square · 2025Article
- Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets.Cell reports. Medicine · 2025Article
- The Molecular Pathology of Blood Cancer: A Comprehensive Review of Chromosome and Genetic Abnormalities and Their Clinical Utility.British journal of biomedical science · 2025Review
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages.Blood cancer journal · 2024Article
- pyComBat, a Python tool for batch effects correction in high-throughput molecular data using empirical Bayes methods.BMC bioinformatics · 2023Article
- SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of 'biomarker-defined early multiple myeloma'-a systematic review with meta-analysis.EClinicalMedicine · 2023Article
- Review
- ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.JCI insight · 2022Article
- Article
- Review
- 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.Haematologica · 2021Review
- MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease.Cancers · 2021Review
- Review
- Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.Nature medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Multiple myeloma is preceded by an asymptomatic phase, comprising monoclonal gammopathy of uncertain significance and smoldering myeloma. Compared to the former, smoldering myeloma has a higher and non-uniform rate of progression to clinical myeloma, reflecting a subset of patients with higher risk. We evaluated the gene expression profile of smoldering myeloma plasma cells among 105 patients enrolled in a prospective observational trial at our institution, with a view to identifying a high-risk signature. Baseline clinical, bone marrow, cytogenetic and radiologic data were evaluated for their potential to predict time to therapy for symptomatic myeloma. A gene signature derived from four genes, at an optimal binary cut-point of 9.28, identified 14 patients (13%) with a 2-year therapy risk of 85.7%. Conversely, a low four-gene score (< 9.28) combined with baseline monoclonal protein < 3 g/dL and albumin ≥ 3.5 g/dL identified 61 patients with low-risk smoldering myeloma with a 5.0% chance of progression at 2 years. The top 40 probe sets showed concordance with indices of chromosome instability. These data demonstrate high discriminatory power of a gene-based assay and suggest a role for dysregulation of mitotic checkpoints in the context of genomic instability as a hallmark of high-risk smoldering myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.